Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Narrative) (Details)

v3.23.1
Significant Accounting Policies (Narrative) (Details)
12 Months Ended
Jul. 22, 2016
shares
Dec. 31, 2022
USD ($)
segment
item
shares
Dec. 31, 2021
USD ($)
shares
Significant Accounting Policies      
Number of subsidiaries | item   0  
Number of operating segments | segment   1  
Number of reportable segments | segment   1  
Restricted cash   $ 1,000,000.0 $ 1,000,000.0
Estimated useful life   5 years  
Property, plant and equipment, gross   $ 17,792,000 16,786,000
Research and development   62,475,000 49,864,000
Accumulated other comprehensive loss   0  
Construction in Process [Member]      
Significant Accounting Policies      
Property, plant and equipment, gross   $ 951,000 $ 2,027,000
Fortress Biotech, Inc [Member]      
Significant Accounting Policies      
Common stock dividend issued (in shares) | shares   2,807,008 2,536,607
Percentage of fully diluted equity   2.50% 2.50%
Fortress Biotech, Inc [Member] | License Agreements [Member]      
Significant Accounting Policies      
Research and development   $ 1,100,000 $ 4,200,000
Fortress Biotech, Inc [Member] | Preferred Class A [Member]      
Significant Accounting Policies      
Preferred stock dividends issued (in shares) | shares 250,000    
Percentage of fully diluted equity 2.50%